Can a common Alzheimer's drug prevent delirium relapse in poisoning patients?
NCT ID NCT06399679
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether rivastigmine, a drug used for Alzheimer's, can prevent delirium from coming back after initial treatment with physostigmine for anticholinergic poisoning. About 42 people aged 10 and older with controlled delirium will receive either rivastigmine or a placebo. The goal is to see if rivastigmine reduces the chance of delirium recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rivastigmine
What this could lead to
If it works, this could provide a longer-lasting treatment option to prevent delirium from returning after initial poisoning control.
What could go wrong
This is a very small, early-phase trial that is currently suspended. Results may not apply to all poisoning cases, and rivastigmine may not work better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTICHOLINERGIC TOXICITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States